Investigational drug · Phase 3
ISL
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV-1 Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
31
Any phase or sponsor naming "ISL"
First trial start
2021
Oct 5, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ISL", any sponsor or status.
- Phase 315
Conditions studied
As listed on its trial records.
- HIV-1 Infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ISL" as an intervention, largest first.
- Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04776252 · 2,000 participants (planned) · Start Sep 15, 2021 · Primary completion May 29, 2029
Drug: MK-8591A · For: HIV-1 Infection
Sites: Phoenix, Arizona; Sacramento, California; Washington D.C., District of Columbia · 93 sites in all
- Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose ReductionPivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT01491815 · 812 participants · Start Dec 14, 2012 · Primary completion Jul 2023
Drug: Non-biological DMARD's; Cimzia and 2 more · For: Rheumatoid Arthritis
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 30 sites in all
- Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04644029 · 730 participants · Start Feb 24, 2021 · Primary completion Jul 18, 2023
Drug: Islatravir; Placebo to FTC/TDF and 2 more · For: HIV-I; Human Immunodeficiency Virus Type 1; Prophylaxis
Sites: Birmingham, Alabama; Washington D.C., District of Columbia; Miami, Florida · 24 sites in all
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04223778 · 672 participants · Start Feb 18, 2020 · Primary completion Sep 8, 2021
Drug: DOR/ISL; ART · For: HIV Infection
Sites: Washington D.C., District of Columbia; Ft. Pierce, Florida; Orlando, Florida · 78 sites in all
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04223791 · 643 participants · Start Feb 18, 2020 · Primary completion Aug 26, 2021
Drug: DOR/ISL; BIC/FTC/TAF and 2 more · For: HIV Infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 89 sites in all
- A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05766501 · 641 participants · Start Mar 17, 2023 · Primary completion Oct 16, 2025
Drug: DOR/ISL · For: HIV Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 95 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630286 · 609 participants · Start Oct 9, 2024 · Primary completion Apr 17, 2026
Drug: ISL/LEN; B/F/TAF and 2 more · For: HIV-1-infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 106 sites in all
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT06630299 · 600 participants (planned) · Start Oct 8, 2024 · Primary completion Apr 23, 2026
Drug: ISL/LEN; Antiretroviral Combinations · For: HIV-1-Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 100 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04233879 · 599 participants · Start Feb 28, 2020 · Primary completion Nov 17, 2022
Drug: DOR/ISL; BIC/FTC/TAF and 2 more · For: HIV-1 Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 95 sites in all
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07266831 · 570 participants (planned) · Start Dec 18, 2025 · Primary completion Feb 1, 2029
Drug: ISL; ULO and 4 more · For: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Sites: Los Angeles, California; Denver, Colorado; Washington D.C., District of Columbia · 56 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Unravelling the multifunctional roles of plant LIM proteins in growth, development, and stress responses.
Kour R, Sharma A, Mishra S, et al. · Plant Sci 2027
- Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.
M Alghzawi H, Shah SZ, Abideen ZU, et al. · HIV Res Clin Pract 2026
- Once-weekly oral islatravir/lenacapavir: Closer to clinical practice?
Clemente T, Castagna A · Med 2026
- Isoliquiritigenin Modulates Quorum Sensing-Associated Neutrophil Extracellular Trap Formation in COPD Isolate Pseudomonas aeruginosa.
Dhanyashree HR, Charavu R, Hameed A, et al. · Molecules 2026
- Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV.
Nussbaum JC, Pham MM, Vargo R, et al. · Antimicrob Agents Chemother 2026
- Neuroendocrine Differentiation in Synovial Sarcoma-An Immunohistochemical Study of 357 Tumors With 4 Markers: Chromogranin A, Synaptophysin, Insulinoma-associated Protein 1 and Insulin Gene Enhancer Protein ISL-1.
Rodriguez Pena MDC, Shah N, Patel M, et al. · Appl Immunohistochem Mol Morphol 2026
Also in development for HIV-1 Infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ULOMK-8507, UlonivirinePhase 33 trials
Merck & Co. · Human Immunodeficiency Virus Type 1 (HIV-1) Infection, HIV-1 Infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- CL-197Phase 21 trial
Henan Genuine Biotech Co., Ltd. · HIV-1 Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.